Fig. 6

In vivo validation of the pro-tumorigenic role of LINC01116. (A) Tumor growth curves in BALB/c nude mice subcutaneously injected with SK-MEL-28 melanoma cells (sh-NC vs. sh-LINC01116 groups). (B) Gross tumor morphology and volumetric analysis at endpoint. Tumor volumes were calculated using the formula: Volume = 0.5×length×width2. The sh-LINC01116 groupshowed markedly smaller tumors compared to the sh-NC group(****P < 0.0001). (C) IHC analysis of Ki67​in tumor tissues. The sh-LINC01116 group displayed significantly fewer Ki67-positive cells than the sh-NC group (***P < 0.001). (D ) TUNEL staining to assess apoptosis in tumor sections. The sh-LINC01116 group exhibited a higher percentage of TUNEL-positive cells (green fluorescence) compared to the sh-NC group (***P < 0.001). (E) WB analysis of stemness-associated markers (Nestin, ABCB5, CD133, ALDH1) in tumor lysates. Data were expressed as the mean ± SD, ***P < 0.001,****P < 0.0001.